Inflammatory bowel disease–associated intestinal fibrosis

키워드

참고문헌 (77)

1. Leask A, "TGF-beta signaling and the fibrotic response", FASEB J, 18, pp.816~827 (2004)
2. Kumar V, "Robbins and Cotran pathologic basis of disease" (2020), Elsevier
3. Jun JI, "Resolution of organ fibrosis", J Clin Invest, 128, pp.97~107 (2018)
4. Di Gregorio J, "The epithelial-to-mesenchymal transition as a possible therapeutic target in fibrotic disorders", Front Cell Dev Biol, 8, pp.607483~ (2020)
5. Rockey DC, "Fibrosis : a common pathway to organ injury and failure", N Engl J Med, 372, pp.1138~1149 (2015)
6. Zhang YZ, "Inflammatory bowel disease : pathogenesis", World J Gastroenterol, 20, pp.91~99 (2014)
7. Zidar N, "Histopathology of fibrosis in Crohn's disease : the importance of understanding its pathogenesis", Gastroenterology, 158, pp.2313~2314 (2020)
8. Hanna MH, "Update on the management of sigmoid diverticulitis", World J Gastroenterol, 27, pp.760~781 (2021)
9. Speca S, "Cellular and molecular mechanisms of intestinal fibrosis", World J Gastroenterol, 18, pp.3635~3661 (2012)
10. Wynn TA, "Cellular and molecular mechanisms of fibrosis", J Pathol, 214, pp.199~210 (2008)
11. Burke JP, "Fibrogenesis in Crohn’s disease", Am J Gastroenterol, 102, pp.439~448 (2007)
12. Franze E, "Cadherin-11 is a regulator of intestinal fibrosis", J Crohns Colitis, 14, pp.406~417 (2020)
13. Rieder F, "Mechanisms, management, and treatment of fibrosis in patients with inflammatory bowel diseases", Gastroenterology, 152, pp.340~350 (2017)
14. Rieder F, "Intestinal fibrosis in inflammatory bowel disease : current knowledge and future perspectives", J Crohns Colitis, 2, pp.279~290 (2008)
15. Derkacz A, "The role of extracellular matrix components in inflammatory bowel diseases", J Clin Med, 10, pp.1122~ (2021)
16. Graham DB, "Pathway paradigms revealed from the genetics of inflammatory bowel disease", Nature, 578, pp.527~539 (2020)
17. Zhang H, "Genetics of inflammatory bowel disease : clues to pathogenesis", Br Med Bull, 87, pp.17~30 (2008)
18. Jerala M, "Expression of fibrosis-related genes in liver and kidney fibrosis in comparison to inflammatory bowel diseases", Cells, 11, pp.314~ (2022)
19. Gazouli M, "NOD2", CARD15, ATG16L1and IL23R gene polymorphisms and childhood-onset of Crohn’s disease, 2010, pp.16, 1753~1758
20. Andriulli A, "The frame-shift mutation of the NOD2", CARD15 gene is significantly increased in ulcerative colitis : an *IG-IBD study, 2004, pp.126, 625~627
21. Wehkamp J, "NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression", Gut, 53, pp.1658~1664 (2004)
22. Nimmo ER, "Genome-wide methylation profiling in Crohn’s disease identifies altered epigenetic regulation of key host defense mechanisms including the Th17 pathway", Inflamm Bowel Dis, 18, pp.889~899 (2012)
23. Chuang AY, "NOD2 expression is regulated by microRNAs in colonic epithelial HCT116 cells", Inflamm Bowel Dis, 20, pp.126~135 (2014)
24. Rieder F, "Predictors of fibrostenotic Crohn’s disease", Inflamm Bowel Dis, 17, pp.2000~2007 (2011)
25. Henckaerts L, "Genetic risk profiling and prediction of disease course in Crohn’s disease patients", Clin Gastroenterol Hepatol, 7, pp.972~980 (2009)
26. Nijhuis A, "In Crohn’s disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts", Clin Sci (Lond), 127, pp.341~350 (2014)
27. Duerr RH, "A genome-wide association study identifies IL23R as an inflammatory bowel disease gene", Science, 314, pp.1461~1463 (2006)
28. Glas J, "rs1004819 is the main diseaseassociated IL23R variant in German Crohn’s disease patients : combined analysis of IL23R, CARD15, and OCTN1", 2 variants, 2007, pp.2, e819~
29. Cleynen I, "Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype : results from the IBDchip European Project", Gut, 62, pp.1556~1565 (2013)
30. Brand S, "Increased expression of the chemokine fractalkine in Crohn’s disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype", Am J Gastroenterol, 101, pp.99~106 (2006)
31. Fowler EV, "ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population : further support for significant disease heterogeneity", Am J Gastroenterol, 103, pp.2519~2526 (2008)
32. Forni D, "ABO histo-blood group might modulate predisposition to Crohn’s disease and affect disease behavior", J Crohns Colitis, 8, pp.489~494 (2014)
33. Hume GE, "Angiotensinogen and transforming growth factor beta1 : novel genes in the pathogenesis of Crohn’s disease", J Med Genet, 43, pp.e51~ (2006)
34. Adams AT, "Two-stage genome-wide methylation profiling in childhood-onset Crohn’s disease implicates epigenetic alterations at the VMP1", MIR21 and HLA loci, 2014, pp.20, 1784~1793
35. Meijer MJ, "Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease", World J Gastroenterol, 13, pp.2960~2966 (2007)
36. Alonso A, "Identification of risk loci for Crohn’s disease phenotypes using a genome-wide association study", Gastroenterology, 148, pp.794~805 (2015)
37. Rieder F, "Wound healing and fibrosis in intestinal disease", Gut, 56, pp.130~139 (2007)
38. Rockey DC, "Hepatic fibrosis, stellate cells, and portal hypertension", Clin Liver Dis, 10, pp.459~479 (2006)
39. Bamba S, "Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice", J Pathol, 209, pp.265~273 (2006)
40. Brittan M, "Gastrointestinal stem cells", J Pathol, 197, pp.492~509 (2002)
41. Mao R, "The mesenteric fat and intestinal muscle interface : creeping fat influencing stricture formation in Crohn’s disease", Inflamm Bowel Dis, 25, pp.421~426 (2019)
42. Peyrin-Biroulet L, "Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn’s disease", Gut, 61, pp.78~85 (2012)
43. Crohn BB, "Regional ileitis : a pathologic and clinical entity", JAMA, 99, pp.1323~1329 (1932)
44. Goncalves P, "Metabolic inflammation in inflammatory bowel disease : crosstalk between adipose tissue and bowel", Inflamm Bowel Dis, 21, pp.453~467 (2015)
45. Desreumaux P, "Inflammatory alterations in mesenteric adipose tissue in Crohn’s disease", Gastroenterology, 117, pp.73~81 (1999)
46. Levine JA, "Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth", J Clin Invest, 101, pp.1557~1564 (1998)
47. Chen W, "Smooth muscle hyperplasia", hypertrophy is the most prominent histological change in Crohn’s fibrostenosing bowel strictures : a semiquantitative analysis by using a novel histological grading scheme, 2017, pp.11, 92~104
48. Kalluri R, "Epithelial-mesenchymal transition and its implications for fibrosis", J Clin Invest, 112, pp.1776~1784 (2003)
49. Zhang D, "Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K", Akt, Int J Oncol, pp.2017, 50[DOI]
50. Frid MG, "Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation : in vitro analysis", Circ Res, 90, pp.1189~1196 (2002)
51. Bates RC, "Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids", Mol Biol Cell, 14, pp.1790~1800 (2003)
52. Strutz F, "Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation", Kidney Int, 61, pp.1714~1728 (2002)
53. Yang J, "A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition", J Am Soc Nephrol, 16, pp.68~78 (2005)
54. Kagawa T, "Hepatocyte growth factor gene therapy slows down the progression of diabetic nephropathy in db", db mice, 2006, pp.102, 92~102
55. D’Alessio S, "Revisiting fibrosis in inflammatory bowel disease : the gut thickens", Nat Rev Gastroenterol Hepatol, 19, pp.169~184 (2022)
56. Chu H, "Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease", Science, 352, pp.1116~1120 (2016)
57. Qiu P, "The gut microbiota in inflammatory bowel disease", Front Cell Infect Microbiol, 12, pp.733992~ (2022)
58. Alfredsson J, "Mechanism of fibrosis and stricture formation in Crohn’s disease", Scand J Immunol, 92, pp.e12990~ (2020)
59. Zhao Z, "Antibiotic alleviates radiation-induced intestinal injury by remodeling microbiota, reducing inflammation, and inhibiting fibrosis", ACS Omega, 5, pp.2967~2977 (2020)
60. Zhao S, "Selective deletion of MyD88 signaling in alpha-SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation", Mucosal Immunol, 13, pp.665~678 (2020)
61. Porras AM, "Inflammatory bowel disease-associated gut commensals degrade components of the extracellular matrix" (2022)[DOI]
62. Knowles CH, "Gastrointestinal neuromuscular pathology in chronic constipation", Best Pract Res Clin Gastroenterol, 25, pp.43~57 (2011)
63. Mosli MH, "Histologic scoring indices for evaluation of disease activity in ulcerative colitis", Cochrane Database Syst Rev, 5, pp.CD011256~ (2017)
64. Hutchings H, "Encyclopedia of quality of life and well-being research", pp.1354~1357 (2014), Springer
65. Sofo L, "New perspectives in the prediction of postoperative complications for high-risk ulcerative colitis patients : machine learning preliminary approach", Eur Rev Med Pharmacol Sci, 24, pp.12781~12787 (2020)
66. Udristoiu AL, "Deep learning algorithm for the confirmation of mucosal healing in Crohn’s disease, based on confocal laser endomicroscopy images", J Gastrointestin Liver Dis, 30, pp.59~65 (2021)
67. Flynn S, "Inflammatory bowel disease presentation and diagnosis", Surg Clin North Am, 99, pp.1051~1062 (2019)
68. Gumaste V, "Benign and malignant colorectal strictures in ulcerative colitis", Gut, 33, pp.938~941 (1992)
69. Mitomi H, "Comparative histologic assessment of proctocolectomy specimens from Japanese and American patients with ulcerative colitis with or without dysplasia", Int J Surg Pathol, 13, pp.259~265 (2005)
70. Yamagata M, "Submucosal fibrosis and basic-fibroblast growth factor-positive neutrophils correlate with colonic stenosis in cases of ulcerative colitis", Digestion, 84, pp.12~21 (2011)
71. Bettenworth D, "Assessment of Crohn’s disease-associated small bowel strictures and fibrosis on cross-sectional imaging : a systematic review", Gut, 68, pp.1115~1126 (2019)
72. Agrawal M, "Approach to the management of recently diagnosed inflammatory bowel disease patients : a user’s guide for adult and pediatric gastroenterologists", Gastroenterology, 161, pp.47~65 (2021)
73. Li C, "Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy", Am J Physiol Renal Physiol, 286, pp.F46~F57 (2004)
74. Abe Y, "Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast", myofibroblast apoptosis in the regeneration, Dig Dis Sci, pp.2012, 57[DOI]
75. Gordon JR, "Amelioration of pathology by ELR-CXC chemokine antagonism in a swine model of airway endotoxin exposure", J Agromedicine, 14, pp.235~241 (2009)
76. Stillie R, "The functional significance behind expressing two IL-8 receptor types on PMN", J Leukoc Biol, 86, pp.529~543 (2009)
77. Speca S, "Novel PPARgamma modulator GED-0507-34 levo ameliorates inflammation-driven intestinal fibrosis", Inflamm Bowel Dis, 22, pp.279~292 (2016)

관련 논문AI추천